Effect of MiYOSMART iQ Spectacle Lenses on Myopia Progression in Children
Recruiting
N/A
Interventional Study
Myopia, Child Myopia Progression
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 8 – 11
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 70 (estimated)
- Sponsor
- Hoya Lens Rus LLC · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This prospective, single-center study aims to evaluate the efficacy and safety of MiYOSMART iQ spectacle lenses with DIMS (Defocus Incorporated Multiple Segments) and Triple Enhanced Design (TED) technology in slowing myopia progression in children aged 8-11 years.
35 children with myopia (spherical equivalent -0.5 to -6.0 D) will be prescribed MiYOSMART iQ lenses and followed for 6 months. The s…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 8-11 years (inclusive)
* Myopia: spherical equivalent -0.5 to -6.0 D under cycloplegia
* No previous myopia control treatment
* Orthophoria, presence of binocular vision
Exclusion Criteria:
* Corrected visual acuity \< 0.8 (decimal)
* Anisometropia \> 2.0 D
* Strabismus …
Contacts